MiR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor

Biochemical and Biophysical Research Communications

Volumn 406, Issue 4, 2011, Pages 518-523

  Park, Jong Kook ^a   Henry, Jon C ^a   Jiang, Jinmai ^a   Esau, Christine ^b   Gusev, Yuriy ^c   Lerner, Megan R ^d   Postier, Russell G ^e   Brackett, Daniel J ^d   Schmittgen, Thomas D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b REGULUS THERAPEUTICS   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

2 adrenergic receptor; Cancer; MicroRNA; Retinoblastoma gene

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; MICRORNA; MIR 132; MIR 212; PROTEIN RB1; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHROMOSOME 17P; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENOCARCINOMA; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; CELL LINE, TUMOR; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; RECEPTORS, ADRENERGIC, BETA-2; RETINOBLASTOMA PROTEIN;

EID: 79953026892     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.065     Document Type: Article

References (33)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60:277-300.
2. Neoptolemos J.P., Stocken D.D., Friess H., Bassi C., Dunn J.A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D.J., Buchler M.W. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004, 350:1200-1210.
3. Simianu V.V., Zyromski N.J., Nakeeb A., Lillemoe K.D. Pancreatic cancer: progress made. Acta Oncol. 2010, 49:407-417.
4. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
5. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103:2257-2261.
6. Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 2007, 120:1046-1054.
7. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
8. Szafranska A.E., Davison T.S., John J., Cannon T., Sipos B., Maghnouj A., Labourier E., Hahn S.A. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26:4442-4452.
9. Zhang Y., Li M., Wang H., Fisher W.E., Lin P.H., Yao Q., Chen C. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J. Surg. 2009, 33:698-709.
10. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
11. Wong T.S., Liu X.B., Chung-Wai Ho A., Po-Wing Yuen A., Wai-Man Ng R., Ignace Wei W. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer 2008, 123:251-257.
12. Anand S., Majeti B.K., Acevedo L.M., Murphy E.A., Mukthavaram R., Scheppke L., Huang M., Shields D.J., Lindquist J.N., Lapinski P.E., King P.D., Weis S.M., Cheresh D.A. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat. Med. 2010, 16:909-914.
13. Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., Liu C.G., Calin G.A., Croce C.M., Harris C.C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
14. Yang L., Belaguli N., Berger D.H. MicroRNA and colorectal cancer. World J. Surg. 2009, 33:638-646.
15. Gougelet A., Pissaloux D., Besse A., Perez J., Duc A., Dutour A., Blay J.Y., Alberti L. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int. J. Cancer 2010.
16. Xu L., Wang F., Xu X.F., Mo W.H., Xia Y.J., Wan R., Wang X.P., Guo C.Y. Down-regulation of miR-212 expression by DNA hypermethylation in human gastric cancer cells. Med. Oncol. 2010.
17. Wada R., Akiyama Y., Hashimoto Y., Fukamachi H., Yuasa Y. MiR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. Int. J. Cancer 2010, 127:1106-1114.
18. Incoronato M., Garofalo M., Urso L., Romano G., Quintavalle C., Zanca C., Iaboni M., Nuovo G., Croce C.M., Condorelli G. MiR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res. 2010, 70:3638-3646.
19. Hatakeyama H., Cheng H., Wirth P., Counsell A., Marcrom S.R., Wood C.B., Pohlmann P.R., Gilbert J., Murphy B., Yarbrough W.G., Wheeler D.L., Harari P.M., Guo Y., Shyr Y., Slebos R.J., Chung C.H. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS ONE 2010, 5:e12702.
20. Park J.K., Lee E.J., Esau C., Schmittgen T.D. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009, 38:e190-e199.
21. Weddle D.L., Tithoff P., Williams M., Schuller H.M. Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas. Carcinogenesis 2001, 22:473-479.
22. Baker J.G., Hall I.P., Hill S.J. Temporal characteristics of cAMP response element-mediated gene transcription: requirement for sustained cAMP production. Mol. Pharmacol. 2004, 65:986-998.
23. Remenyi J., Hunter C.J., Cole C., Ando H., Impey S., Monk C.E., Martin K.J., Barton G.J., Hutvagner G., Arthur J.S. Regulation of the miR-212/132 locus by MSK1 and CREB in response to neurotrophins. Biochem. J. 2010, 428:281-291.
24. Barton C.M., McKie A.B., Hogg A., Bia B., Elia G., Phillips S.M., Ding S.F., Lemoine N.R. Abnormalities of the RB1 and DCC tumor suppressor genes: uncommon in human pancreatic adenocarcinoma. Mol. Carcinog. 1995, 13:61-69.
25. Huang L., Lang D., Geradts J., Obara T., Klein-Szanto A.J., Lynch H.T., Ruggeri B.A. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. Mol. Carcinog. 1996, 15:85-95.
26. Semizarov D., Kroeger P., Fesik S. SiRNA-mediated gene silencing: a global genome view. Nucl. Acids Res. 2004, 32:3836-3845.
27. Dyson N. The regulation of E2F by pRB-family proteins. Genes. Dev. 1998, 12:2245-2262.
28. Naderi S., Hunton I.C., Wang J.Y. Radiation dose-dependent maintenance of G(2) arrest requires retinoblastoma protein. Cell Cycle 2002, 1:193-200.
29. Kimura S.H., Ikawa M., Ito A., Okabe M., Nojima H. Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene 2001, 20:3290-3300.
30. Vo N., Klein M.E., Varlamova O., Keller D.M., Yamamoto T., Goodman R.H., Impey S. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc. Natl. Acad. Sci. USA 2005, 102:16426-16431.
31. Lagos D., Pollara G., Henderson S., Gratrix F., Fabani M., Milne R.S., Gotch F., Boshoff C. MiR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat. Cell Biol. 2010, 12:513-519.
32. Schuller H.M. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat. Rev. Cancer 2002, 2:455-463.
33. Zhang D., Ma Q.Y., Hu H.T., Zhang M. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol. Ther. 2010, 10:19-29.